Targeted delivery of a SNARE protease to sensory neurons using a single chain antibody (scFv) against the extracellular domain of P2X3 inhibits the release of a pain mediator

A single-chain antibody was generated against an extracellular domain of human P2X3 as a targeting moiety. It was conjugated with a pain therapeutic SNARE protease derived from BoNT/A to demonstrate its intracellular delivery into pain-sensing neurons.

Download Full-text

Targeting the Tumor Microenvironment with Fluorescence-Activatable Bispecific Endoglin/Fibroblast Activation Protein Targeting Liposomes

Pharmaceutics ◽

10.3390/pharmaceutics12040370 ◽

2020 ◽

Vol 12 (4) ◽

pp. 370 ◽

Cited By ~ 2

Author(s):

Felista L. Tansi ◽

Ronny Rüger ◽

Ansgar M. Kollmeier ◽

Markus Rabenhold ◽

Frank Steiniger ◽

...

Keyword(s):

Tumor Microenvironment ◽

Targeted Delivery ◽

Near Infrared ◽

Fibroblast Activation Protein ◽

Target Cells ◽

Single Chain ◽

High Concentration ◽

Single Chain Antibody ◽

Stromal Fibroblasts ◽

Fibroblast Activation

Liposomes are biocompatible nanocarriers with promising features for targeted delivery of contrast agents and drugs into the tumor microenvironment, for imaging and therapy purposes. Liposome-based simultaneous targeting of tumor associated fibroblast and the vasculature is promising, but the heterogeneity of tumors entails a thorough validation of suitable markers for targeted delivery. Thus, we elucidated the potential of bispecific liposomes targeting the fibroblast activation protein (FAP) on tumor stromal fibroblasts, together with endoglin which is overexpressed on tumor neovascular cells and some neoplastic cells. Fluorescence-quenched liposomes were prepared by hydrating a lipid film with a high concentration of the self-quenching near-infrared fluorescent dye, DY-676-COOH, to enable fluorescence detection exclusively upon liposomal degradation and subsequent activation. A non-quenched green fluorescent phospholipid was embedded in the liposomal surface to fluorescence-track intact liposomes. FAP- and murine endoglin-specific single chain antibody fragments were coupled to the liposomal surface, and the liposomal potentials validated in tumor cells and mice models. The bispecific liposomes revealed strong fluorescence quenching, activatability, and selectivity for target cells and delivered the encapsulated dye selectively into tumor vessels and tumor associated fibroblasts in xenografted mice models and enabled their fluorescence imaging. Furthermore, detection of swollen lymph nodes during intra-operative simulations was possible. Thus, the bispecific liposomes have potentials for targeted delivery into the tumor microenvironment and for image-guided surgery.

Download Full-text

Targeted RNAi of BIRC5/Survivin Using Antibody-Conjugated Poly(Propylene Imine)-Based Polyplexes Inhibits Growth of PSCA-Positive Tumors

Pharmaceutics ◽

10.3390/pharmaceutics13050676 ◽

2021 ◽

Vol 13 (5) ◽

pp. 676

Author(s):

Willi Jugel ◽

Achim Aigner ◽

Susanne Michen ◽

Alexander Hagstotz ◽

Alexander Ewe ◽

...

Keyword(s):

Targeted Delivery ◽

Survivin Expression ◽

Firefly Luciferase ◽

Dendritic Polymers ◽

Single Chain ◽

Single Chain Antibody ◽

Therapeutic Study ◽

Poly Propylene

Delivery of siRNAs for the treatment of tumors critically depends on the development of efficient nucleic acid carrier systems. The complexation of dendritic polymers (dendrimers) results in nanoparticles, called dendriplexes, that protect siRNA from degradation and mediate non-specific cellular uptake of siRNA. However, large siRNA doses are required for in vivo use due to accumulation of the nanoparticles in sinks such as the lung, liver, and spleen. This suggests the exploration of targeted nanoparticles for enhancing tumor cell specificity and achieving higher siRNA levels in tumors. In this work, we report on the targeted delivery of a therapeutic siRNA specific for BIRC5/Survivin in vitro and in vivo to tumor cells expressing the surface marker prostate stem cell antigen (PSCA). For this, polyplexes consisting of single-chain antibody fragments specific for PSCA conjugated to siRNA/maltose-modified poly(propylene imine) dendriplexes were used. These polyplexes were endocytosed by PSCA-positive 293TPSCA/ffLuc and PC3PSCA cells and caused knockdown of reporter gene firefly luciferase and Survivin expression, respectively. In a therapeutic study in PC3PSCA xenograft-bearing mice, significant anti-tumor effects were observed upon systemic administration of the targeted polyplexes. This indicates superior anti-tumor efficacy when employing targeted delivery of Survivin-specific siRNA, based on the additive effects of siRNA-mediated Survivin knockdown in combination with scFv-mediated PSCA inhibition.

Download Full-text

Targeted delivery of TLR3 agonist to tumor cells with single chain antibody fragment-conjugated nanoparticles induces type I-interferon response and apoptosis

Scientific Reports ◽

10.1038/s41598-019-40032-8 ◽

2019 ◽

Vol 9 (1) ◽

Cited By ~ 12

Author(s):

Isabell Schau ◽

Susanne Michen ◽

Alexander Hagstotz ◽

Andreas Janke ◽

Gabriele Schackert ◽

...

Keyword(s):

Tumor Cells ◽

Targeted Delivery ◽

Type I Interferon ◽

Antibody Fragment ◽

Interferon Response ◽

Type I ◽

Single Chain ◽

Single Chain Antibody ◽

Single Chain Antibody Fragment

Download Full-text

Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins

Experimental Biology and Medicine ◽

10.1177/1535370217748575 ◽

2017 ◽

Vol 243 (2) ◽

pp. 166-183 ◽

Cited By ~ 8

Author(s):

Christian Fercher ◽

Sahar Keshvari ◽

Michael A McGuckin ◽

Ross T Barnard

Keyword(s):

Targeted Delivery ◽

Treatment Options ◽

Specific Antigen ◽

Antibody Fragment ◽

Magic Bullet ◽

Full Potential ◽

Single Chain ◽

Single Chain Antibody ◽

Adequate Treatment ◽

Preclinical And Clinical Studies

Immunocytokines are fusion proteins that combine the specific antigen binding capacities of an antibody or derivative thereof and the potent bioactivity of a cytokine partner. These novel biopharmaceuticals have been directed to various targets of oncological as well as non-oncological origin and a handful of promising constructs are currently advancing in the clinical trial pipeline. Several factors such as the choice of a disease specific antigen, the antibody format and the modulatory nature of the payload are crucial, not only for therapeutic efficacy and safety but also for the commercial success of such a product. In this review, we provide an overview of the basic principles and obstacles in immunocytokine design with a specific focus on single chain antibody fragment-based constructs that employ interleukins as the immunoactive component. Impact statement Selective activation of the immune system in a variety of malignancies represents an attractive approach when existing strategies have failed to provide adequate treatment options. Immunocytokines as a novel class of bifunctional protein therapeutics have emerged recently and generated promising results in preclinical and clinical studies. In order to harness their full potential, multiple different aspects have to be taken into consideration. Several key points of these fusion constructs are discussed here and should provide an outline for the development of novel products based on an overview of selected formats.

Download Full-text

Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells

Molecular Cancer Therapeutics ◽

10.1158/1535-7163.mct-07-0140 ◽

2007 ◽

Vol 6 (10) ◽

pp. 2737-2746 ◽

Cited By ~ 59

Author(s):

A. Roth ◽

D. C. Drummond ◽

F. Conrad ◽

M. E. Hayes ◽

D. B. Kirpotin ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Cells ◽

Intracellular Delivery ◽

Prostate Cancer Cells ◽

Single Chain ◽

Single Chain Antibody ◽

Liposomal Drugs

Download Full-text

A Poly(Propyleneimine) Dendrimer-Based Polyplex-System for Single-Chain Antibody-Mediated Targeted Delivery and Cellular Uptake of SiRNA

Small ◽

10.1002/smll.201700072 ◽

2017 ◽

Vol 13 (27) ◽

pp. 1700072 ◽

Cited By ~ 24

Author(s):

Stefanie Tietze ◽

Isabell Schau ◽

Susanne Michen ◽

Franka Ennen ◽

Andreas Janke ◽

...

Keyword(s):

Cellular Uptake ◽

Targeted Delivery ◽

Single Chain ◽

Single Chain Antibody

Download Full-text

Synthesis of a tumorspecific single-chain antibody and derivatives in E. coli and COS-1 cells

Immunology Letters ◽

10.1016/s0165-2478(97)87603-1 ◽

1997 ◽

Vol 56 (1-3) ◽

pp. 191

Author(s):

S Dincq

Keyword(s):

Single Chain ◽

Single Chain Antibody ◽

E Coli

Download Full-text

Faculty Opinions recommendation of Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727478988.793531115 ◽

2017 ◽

Author(s):

Martin Gruebele ◽

Max Platkov

Keyword(s):

Mouse Model ◽

Transgenic Mouse ◽

Transgenic Mouse Model ◽

Combined Effects ◽

Single Chain ◽

Single Chain Antibody

Download Full-text

Single-chain Antibody Against Reg4 Suppresses Gastric Cancer Cell Growth and Enhances 5-FU-induced Cell Death in vitro

Anti-Cancer Agents in Medicinal Chemistry ◽

10.2174/1871520619666181122104720 ◽

2019 ◽

Vol 19 (5) ◽

pp. 610-619 ◽

Cited By ~ 3

Author(s):

Xue-Qing Zhang ◽

Lu-Ting Yu ◽

Pei Du ◽

Tian-Qi Yin ◽

Zhi-Yuan Zhang ◽

...

Keyword(s):

Gastric Cancer ◽

Cell Proliferation ◽

Cell Death ◽

Cancer Cell ◽

Gastric Cancer Cell ◽

Single Chain ◽

Single Chain Antibody ◽

Ags Cells ◽

Thiazolyl Blue Tetrazolium Bromide

Background:Regenerating islet-derived gene family member 4 (Reg4), a well-investigated growth factor in the regenerative pancreas, has recently been reported to be highly associated with a majority of gastrointestinal cancers. Pathological hyper-expression or artificial over-expression of Reg4 causes acceleration of tumor growth, migration, and resistance to chemotherapeutic 5-Fluorouracil (5-FU). Until now, no method has been successfully established for eliminating the effects of Reg4 protein.Methods:This study reports the production of an engineered immunoglobin, a single-chain variable fragment (scFv-Reg4), to specifically bind Reg4 and block the bioactivity. The complementary-determining regions (CDRs) against Reg4 were assigned using MOE and ZDOCK servers. The binding affinity (KD) was determined by bio-layer interferometry (BLI). MKN45 and AGS cell proliferation was determined by Thiazolyl blue tetrazolium bromide (MTT) method and the cell apoptosis was detected by flow cytometry assay.Results:The KD of scFv-Reg4 to Reg4 was determined to be 1.91×10-8. In MKN45 and AGS cell lines, scFv- Reg4 depressed Reg4-stimulated cell proliferation and the inhibitory rates were 27.7±1.5% and 17.3±2.6%, respectively. Furthermore, scFv significantly enhanced 5-FU-induced cell death, from 23.0±1.0% to 28.4±1.2% in MKN45 and 28.2±0.7% to 36.6±0.6% in AGS cells. Treatment with scFv alone could lyse cancer cells to a certain extent, but no significance has been observed.Conclusion:The single-chain antibody (scFv-Reg4) significantly inhibited gastric cancer cell proliferation and synergistically enhanced the lethal effect of 5-FU. Thus, traditional chemo-/radio- therapeutics supplemented with scFv-Reg4 may provide advances in the strategy for gastrointestinal cancer treatment.

Download Full-text